Navigation Links
Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Science's Inaugural Conference
Date:3/28/2008

Global Pharmaceutical Company Supports Organization's National Networking

And Expo Event

MORRISTOWN, N.J., March 28 /PRNewswire/ -- Diversity Alliance for Science, Inc. (DA4S) (http://www.diversityallianceforscience.com) has announced that Merck & Co., Inc. will serve as the keynote sponsor for its inaugural networking conference and expo scheduled for May 19-20 at the Westin Governors in Morristown, N.J. The two-day event will focus on developing and integrating more minority, women, veteran and disabled-owned businesses into the life sciences space. The national event is expected to draw top-level pharmaceutical executives, high-ranking government officials and CEOs of diverse scientific and clinical enterprises.

Merck & Co, Inc. is one of the largest pharmaceutical companies in the world. Established in 1891 and headquartered in Whitehouse Station, N.J., the company discovers, develops, manufactures and markets a broad range of products aimed at improving human and animal health. Merck has 59,800-plus employees worldwide and products sold in more than 140 countries. The company boasts a Manufacturing Division, which employs more than 12,000 people at locations in 25 countries, as well as The Merck Research Laboratories, which employs approximately 9,500 people at sites in the U.S., Canada, Europe and Asia. Through The Merck Foundation, founded in 1957, the company has distributed more than $480 million to educational and nonprofit organizations worldwide.

"Merck's success has been built from the diversity of its employees and from a diverse customer base," said Sally Macaluso, senior director of global procurement for Merck & Co., Inc. "One of Merck's key corporate objectives is to grow supplier diversity spend to support the diverse communities in which we do business. As such, Merck is a proud sponsor of Diversity Alliance For Science's 'Diversity Creates Scientific Innovation Conference and Expo.'"

About Diversity Alliance for Science, Inc. (DA4S):

Diversity Alliance for Science, Inc. (DA4S) is a nonprofit organization aimed to provide pharmaceutical/bio-tech companies, academic medical centers and governmental agencies the ability to identify, develop, mentor and partner with woman, minority, veteran and disabled-owned enterprises (both large and small) in the life sciences industry. For more information, please visit http://www.diversityallianceforscience.com.

Patty Briguglio

MMI Associates, Inc.

(919) 233-6600

patty@mmimarketing.com

PR Firms Raleigh, NC


'/>"/>
SOURCE Diversity Alliance for Science, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
2. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
8. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
11. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/22/2017)... 22, 2017   Invitae Corporation (NYSE: ... companies, today announced the availability of a new ... Muscular Atrophy (SMA) , a neuromuscular disease that ... among infants as well as a significant cause ... test, announced during the American College of Medical ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... interfere with the ability of endogenous hormones to regulate homeostasis via their ... activity (antagonists), EDCs produce adverse reproductive, neurological, proliferative, and immunological disorders. EDC ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen ... today announced that it has entered into an exclusive global license agreement with ... disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
Breaking Biology News(10 mins):